Similarly, the IDH1 and IDH2 inhibitors ivosidenib and enasidenib have shown promising results in clinical trials and have been approved for use in AML patients with IDH1 and IDH2 mutations, respectively [59, 60]. Here, IDH2 is linked to acute myeloid leukemia.